Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Aurovela 24 Fe

×

Overview

What is Aurovela 24 Fe?

Aurovela 24 Fe is a combination oral contraceptive for oral administration consisting of active tablets containing norethindrone acetate, a progestin, and ethinyl estradiol, an estrogen, and placebo tablets containing ferrous fumarate, which serve no therapeutic purpose.

The chemical name of ethinyl estradiol is 19-nor-17α-pregna-1,3,5(10)-trien-20-yne-3,17-diol. The molecular formula of ethinyl estradiol is CHO and the structural formula is:

The chemical name of norethindrone acetate is 17-hydroxy-19-nor-17α-pregn-4-en-20-yn-3-one acetate. The molecular formula of norethindrone acetate is CHOand the structural formula is:

 

 

USP Dissolution Test Pending.



What does Aurovela 24 Fe look like?



What are the available doses of Aurovela 24 Fe?

Aurovela 24 Fe consists of 28 tablets in the following order ():

What should I talk to my health care provider before I take Aurovela 24 Fe?

How should I use Aurovela 24 Fe?

Aurovela 24 Fe is indicated for use by women to prevent pregnancy .

The efficacy of Aurovela 24 Fe in women with a body mass index (BMI) of greater than 35 kg/mhas not been evaluated.

Aurovela 24 Fe is available in a blister pack Aurovela 24 Fe may be started using either a Day 1 start or a Sunday start (see Table 1). For the first cycle of a Sunday Start regimen, an additional method of contraception must be used until after the first 7 consecutive days of administration.


What interacts with Aurovela 24 Fe?

Sorry No Records found


What are the warnings of Aurovela 24 Fe?

Sorry No Records found


What are the precautions of Aurovela 24 Fe?

Sorry No Records found


What are the side effects of Aurovela 24 Fe?

Sorry No records found


What should I look out for while using Aurovela 24 Fe?

Do not prescribe Aurovela 24 Fe to women who are known to have the following conditions:

Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke .


What might happen if I take too much Aurovela 24 Fe?

There have been no reports of serious ill effects from overdose of oral contraceptives, including ingestion by children. Overdosage may cause withdrawal bleeding in females and nausea.


How should I store and handle Aurovela 24 Fe?

Store Drax Exametazime kit at 15°C - 25°C (59°F - 77°F).Drax Exametazime is for distribution to and use by persons licensed authorized by the U.S. Nuclear Regulatory Commission or the relevant regulatory authority of an Agreement State. Store and dispose of technetium Tc 99m exametazime in compliance with the appropriate regulations of the government agency authorized to license the use of this radionuclide.Product: 63629-4022NDC: 63629-4022-1 30 TABLET, FILM COATED in a BOTTLENDC: 63629-4022-2 10 TABLET, FILM COATED in a BOTTLEProduct: 63629-4306NDC: 63629-4306-2 10 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-3 5 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-1 30 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-0 3 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-4 4 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-5 6 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-6 14 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-7 60 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-8 12 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-9 90 TABLET, ORALLY DISINTEGRATING in a BOTTLEProduct: 63629-4022NDC: 63629-4022-1 30 TABLET, FILM COATED in a BOTTLENDC: 63629-4022-2 10 TABLET, FILM COATED in a BOTTLEProduct: 63629-4306NDC: 63629-4306-2 10 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-3 5 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-1 30 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-0 3 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-4 4 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-5 6 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-6 14 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-7 60 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-8 12 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-9 90 TABLET, ORALLY DISINTEGRATING in a BOTTLEProduct: 63629-4022NDC: 63629-4022-1 30 TABLET, FILM COATED in a BOTTLENDC: 63629-4022-2 10 TABLET, FILM COATED in a BOTTLEProduct: 63629-4306NDC: 63629-4306-2 10 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-3 5 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-1 30 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-0 3 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-4 4 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-5 6 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-6 14 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-7 60 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-8 12 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-9 90 TABLET, ORALLY DISINTEGRATING in a BOTTLEProduct: 63629-4022NDC: 63629-4022-1 30 TABLET, FILM COATED in a BOTTLENDC: 63629-4022-2 10 TABLET, FILM COATED in a BOTTLEProduct: 63629-4306NDC: 63629-4306-2 10 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-3 5 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-1 30 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-0 3 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-4 4 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-5 6 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-6 14 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-7 60 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-8 12 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-9 90 TABLET, ORALLY DISINTEGRATING in a BOTTLEProduct: 63629-4022NDC: 63629-4022-1 30 TABLET, FILM COATED in a BOTTLENDC: 63629-4022-2 10 TABLET, FILM COATED in a BOTTLEProduct: 63629-4306NDC: 63629-4306-2 10 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-3 5 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-1 30 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-0 3 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-4 4 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-5 6 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-6 14 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-7 60 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-8 12 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-9 90 TABLET, ORALLY DISINTEGRATING in a BOTTLEProduct: 63629-4022NDC: 63629-4022-1 30 TABLET, FILM COATED in a BOTTLENDC: 63629-4022-2 10 TABLET, FILM COATED in a BOTTLEProduct: 63629-4306NDC: 63629-4306-2 10 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-3 5 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-1 30 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-0 3 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-4 4 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-5 6 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-6 14 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-7 60 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-8 12 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-9 90 TABLET, ORALLY DISINTEGRATING in a BOTTLEProduct: 63629-4022NDC: 63629-4022-1 30 TABLET, FILM COATED in a BOTTLENDC: 63629-4022-2 10 TABLET, FILM COATED in a BOTTLEProduct: 63629-4306NDC: 63629-4306-2 10 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-3 5 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-1 30 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-0 3 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-4 4 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-5 6 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-6 14 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-7 60 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-8 12 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-9 90 TABLET, ORALLY DISINTEGRATING in a BOTTLEProduct: 63629-4022NDC: 63629-4022-1 30 TABLET, FILM COATED in a BOTTLENDC: 63629-4022-2 10 TABLET, FILM COATED in a BOTTLEProduct: 63629-4306NDC: 63629-4306-2 10 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-3 5 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-1 30 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-0 3 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-4 4 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-5 6 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-6 14 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-7 60 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-8 12 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-9 90 TABLET, ORALLY DISINTEGRATING in a BOTTLEProduct: 63629-4022NDC: 63629-4022-1 30 TABLET, FILM COATED in a BOTTLENDC: 63629-4022-2 10 TABLET, FILM COATED in a BOTTLEProduct: 63629-4306NDC: 63629-4306-2 10 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-3 5 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-1 30 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-0 3 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-4 4 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-5 6 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-6 14 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-7 60 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-8 12 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-9 90 TABLET, ORALLY DISINTEGRATING in a BOTTLEProduct: 63629-4022NDC: 63629-4022-1 30 TABLET, FILM COATED in a BOTTLENDC: 63629-4022-2 10 TABLET, FILM COATED in a BOTTLEProduct: 63629-4306NDC: 63629-4306-2 10 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-3 5 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-1 30 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-0 3 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-4 4 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-5 6 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-6 14 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-7 60 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-8 12 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-9 90 TABLET, ORALLY DISINTEGRATING in a BOTTLEProduct: 63629-4022NDC: 63629-4022-1 30 TABLET, FILM COATED in a BOTTLENDC: 63629-4022-2 10 TABLET, FILM COATED in a BOTTLEProduct: 63629-4306NDC: 63629-4306-2 10 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-3 5 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-1 30 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-0 3 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-4 4 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-5 6 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-6 14 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-7 60 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-8 12 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-9 90 TABLET, ORALLY DISINTEGRATING in a BOTTLEProduct: 63629-4022NDC: 63629-4022-1 30 TABLET, FILM COATED in a BOTTLENDC: 63629-4022-2 10 TABLET, FILM COATED in a BOTTLEProduct: 63629-4306NDC: 63629-4306-2 10 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-3 5 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-1 30 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-0 3 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-4 4 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-5 6 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-6 14 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-7 60 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-8 12 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-9 90 TABLET, ORALLY DISINTEGRATING in a BOTTLEProduct: 63629-4022NDC: 63629-4022-1 30 TABLET, FILM COATED in a BOTTLENDC: 63629-4022-2 10 TABLET, FILM COATED in a BOTTLEProduct: 63629-4306NDC: 63629-4306-2 10 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-3 5 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-1 30 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-0 3 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-4 4 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-5 6 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-6 14 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-7 60 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-8 12 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-9 90 TABLET, ORALLY DISINTEGRATING in a BOTTLEProduct: 63629-4022NDC: 63629-4022-1 30 TABLET, FILM COATED in a BOTTLENDC: 63629-4022-2 10 TABLET, FILM COATED in a BOTTLEProduct: 63629-4306NDC: 63629-4306-2 10 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-3 5 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-1 30 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-0 3 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-4 4 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-5 6 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-6 14 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-7 60 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-8 12 TABLET, ORALLY DISINTEGRATING in a BOTTLENDC: 63629-4306-9 90 TABLET, ORALLY DISINTEGRATING in a BOTTLE


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

COCs lower the risk of becoming pregnant primarily by suppressing ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation.

Non-Clinical Toxicology
Do not prescribe Aurovela 24 Fe to women who are known to have the following conditions:

Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke .

Potential Effects of Coadministration of Drugs Highly Bound to Plasma Proteins

In a study comparing prothrombin time AUC (0-120 hr) following dosing with warfarin (0.75 mg/kg) before and after 21 days of dosing with either sertraline hydrochloride (50-200 mg/day) or placebo, there was a mean increase in prothrombin time of 8% relative to baseline for sertraline hydrochloride compared to a 1% decrease for placebo (p<0.02). The normalization of prothrombin time for the sertraline hydrochloride group was delayed compared to the placebo group. The clinical significance of this change is unknown. Accordingly, prothrombin time should be carefully monitored when sertraline hydrochloride therapy is initiated or stopped.

Cimetidine

CNS Active Drugs

In a placebo-controlled trial in normal volunteers, the administration of two doses of Sertraline hydrochloride did not significantly alter steady-state lithium levels or the renal clearance of lithium.

Nonetheless, at this time, it is recommended that plasma lithium levels be monitored following initiation of Sertraline hydrochloride therapy with appropriate adjustments to the lithium dose.

In a controlled study of a single dose (2 mg) of pimozide, 200 mg sertraline (q.d.) co-administration to steady state was associated with a mean increase in pimozide AUC and C of about 40%, but was not associated with any changes in EKG. Since the highest recommended pimozide dose (10 mg) has not been evaluated in combination with sertraline, the effect on QT interval and PK parameters at doses higher than 2 mg at this time are not known. While the mechanism of this interaction is unknown, due to the narrow therapeutic index of pimozide and due to the interaction noted at a low dose of pimozide, concomitant administration of Sertraline hydrochloride and pimozide should be contraindicated (see ).

Results of a placebo-controlled trail in normal volunteers suggest that chronic administration of sertraline 200 mg/day does not produce clinically important inhibition of phenytoin metabolism. Nonetheless, at this time, it is recommended that plasma phenytoin concentrations be monitored following initiation of Sertraline Hydrochloride therapy with appropriate adjustments to the phenytoin dose, particularly in patients with multiple underlying medical conditions and/or those receiving multiple concomitant medications.

The effect of Sertraline hydrochloride on valproate levels has not been evaluated in clinical trials. In the absence of such data, it is recommended that plasma valproate levels be monitored following initiation of Sertraline hydrochloride therapy with appropriate adjustments to the valproate dose.

The risk of using sertraline hydrochloride in combination with other CNS active drugs has not been systematically evaluated. Consequently, caution is advised if the concomitant administration of sertraline hydrochloride and such drugs is required.

There is limited controlled experience regarding the optimal timing of switching from other drugs effective in the treatment of major depressive disorder, premenstrual dysphoric disorder to sertraline hydrochloride. Care and prudent medical judgment should be exercised when switching, particularly from long-acting agents. The duration of an appropriate washout period which should intervene before switching from one selective serotonin reuptake inhibitor (SSRI) to another has not been established.

Monoamine Oxidase Inhibitors





Drugs Metabolized by P450 2D6

Serotonergic Drugs:

Triptans:

Sumatriptan

Tricyclic Antidepressant Drugs Effective in the Treatment of Major Depressive Disorder (TCAs)

Hypoglycemic Drugs

Atenolol

Digoxin

Microsomal Enzyme Induction

Drugs that Interfere with Hemostasis (Non-selective NSAIDs, Aspirin, Warfarin, etc.)

Serotonin release by platelets plays an important role in hemostasis. Epidemiological studies of  the case-control and cohort design that have demonstrated an association between use of  psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin may  potentiate this risk of bleeding. These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding. Altered anticoagulant effects, including increased bleeding, have been reported when SSRIs or SNRIs are coadministered with warfarin. Patients receiving warfarin therapy should be carefully monitored when Sertraline hydrochloride is initiated or discontinued.

Electroconvulsive Therapy

Alcohol

Carcinogenesis







Impairment of Fertility





Pregnancy-Nonteratogenic Effects

Infants exposed to SSRIs in pregnancy may have an increased risk for persistent pulmonary hypertension of the newborn (PPHN). PPHN occurs in 1 – 2 per 1,000 live births in the general population and is associated with substantial neonatal morbidity and mortality. Several recent epidemiologic studies suggest a positive statistical association between SSRI use (including sertraline hydrochloride) in pregnancy and PPHN. Other studies do not show a significant statistical association.

Physicians should also note the results of a prospective longitudinal study of 201 pregnant women with a history of major depression, who were either on antidepressants or had received antidepressants less than 12 weeks prior to their last menstrual period, and were in remission. Women who discontinued antidepressant medication during pregnancy showed a significant increase in relapse of their major depression compared to those women who remained on antidepressant medication throughout pregnancy.

When treating a pregnant woman with sertraline hydrochloride, the physician should carefully consider both the potential risks of taking an SSRI, along with the established benefits of treating depression with an antidepressant. This decision can only be made on a case by case basis (see ).

Labor and Delivery

Nursing Mothers

Pediatric Use

The safety of Sertraline hydrochloride use in children and adolescents with OCD, ages 6-18, was evaluated in a 12-week, multicenter, placebo-controlled study with 187 outpatients, ages 6-17, and in a flexible dose, 52 week open extension study of 137 patients, ages 6-18, who had completed the initial 12week, double-blind, placebo-controlled study. Sertraline hydrochloride was administered at doses of either 25 mg/day (children, ages 6-12) or 50 mg/day (adolescents, ages 13-18) and then titrated in weekly 25 mg/day or 50 mg/day increments, respectively, to a maximum dose of 200 mg/day based upon clinical response. The mean dose for completers was 157 mg/day. In the acute 12 week pediatric study and in the 52 week study, Sertraline hydrochloride had an adverse event profile generally similar to that observed in adults.

Sertraline pharmacokinetics were evaluated in 61 pediatric patients between 6 and 17 years of age with major depressive disorder or OCD and revealed similar drug exposures to those of adults when plasma concentration was adjusted for weight (see under ).

Approximately 600 patients with major depressive disorder or OCD between 6 and 17 years of age have received Sertraline hydrochloride in clinical trials, both controlled and uncontrolled. The adverse event profile observed in these patients was generally similar to that observed in adult studies with sertraline hydrochloride (see ). As with other SSRIs, decreased appetite and weight loss have been observed in association with the use of Sertraline hydrochloride. In a pooled analysis of two 10-week, double-blind, placebo-controlled, flexible dose (50-200 mg) outpatient trials for major depressive disorder (n=373), there was a difference in weight change between sertraline and placebo of roughly 1 kilogram, for both children (ages 6-11) and adolescents (ages 12-17), in both cases representing a slight weight loss for sertraline compared to a slight gain for placebo. At baseline the mean weight for children was 39.0 kg for sertraline and 38.5 kg for placebo. At baseline the mean weight for adolescents was 61.4 kg for sertraline and 62.5 kg for placebo. There was a bigger difference between sertraline and placebo in the proportion of outliers for clinically important weight loss in children than in adolescents. For children, about 7% had a weight loss > 7% of body weight compared to none of the placebo patients; for adolescents, about 2% had a weight loss > 7% of body weight compared to about 1% of the placebo patients. A subset of these patients who completed the randomized controlled trials (sertraline n=99, placebo n=122) were continued into a 24-week, flexible-dose, open-label, extension study. A mean weight loss of approximately 0.5 kg was seen during the first eight weeks of treatment for subjects with first exposure to sertraline during the open-label extension study, similar to mean weight loss observed among sertraline treated subjects during the first eight weeks of the randomized controlled trials. The subjects continuing in the open label study began gaining weight compared to baseline by week 12 of sertraline treatment. Those subjects who completed 34 weeks of sertraline treatment (10 weeks in a placebo controlled trial + 24 weeks open label, n=68) had weight gain that was similar to that expected using data from age-adjusted peers. Regular monitoring of weight and growth is recommended if treatment of a pediatric patient with an SSRI is to be continued long term. Safety and effectiveness in pediatric patients below the age of 6 have not been established.

The risks, if any, that may be associated with Sertraline hydrochloride’s use beyond 1 year in children and adolescents with OCD or major depressive disorder have not been systematically assessed. The prescriber should be mindful that the evidence relied upon to conclude that sertraline is safe for use in children and adolescents derives from clinical studies that were 10 to 52 weeks in duration and from the extrapolation of experience gained with adult patients. In particular, there are no studies that directly evaluate the effects of long-term sertraline use on the growth, development, and maturation of children and adolescents. Although there is no affirmative finding to suggest that sertraline possesses a capacity to adversely affect growth, development or maturation, the absence of such findings is not compelling evidence of the absence of the potential of sertraline to have adverse effects in chronic use (see – Clinical Worsening and Suicide Risk).

Geriatric Use

Other Adverse Events in Geriatric Patients. In 354 geriatric subjects treated with Sertraline hydrochloride in placebo-controlled trials, the overall profile of adverse events was generally similar to that shown in Tables 2 and 3. Urinary tract infection was the only adverse event not appearing in Tables 2 and 3 and reported at an incidence of at least 2% and at a rate greater than placebo in placebo-controlled trials.

SSRIS and SNRIs, including Sertraline hydrochloride, have been associated with cases of clinically significant hyponatremia in elderly patients, who may be at greater risk for this adverse event (see , Hyponatremia).

Thrombotic Disorders and Other Vascular Problems: Stop Aurovela 24 Fe if a thrombotic event occurs. Stop at least 4 weeks before through 2 weeks after major surgery. Start no earlier than 4 weeks after delivery, in women who are not breastfeeding. 

Liver disease: Discontinue Aurovela 24 Fe if jaundice occurs. 

High blood pressure: If used in women with well-controlled hypertension, monitor blood pressure and stop Aurovela 24 Fe if blood pressure rises significantly. ()

Carbohydrate and lipid metabolic effects: Monitor prediabetic and diabetic women taking Aurovela 24 Fe. Consider an alternative contraceptive method for women with uncontrolled dyslipidemia. ()

Headache: Evaluate significant change in headaches and discontinue Aurovela 24 Fe if indicated. ()

 Bleeding Irregularities and Amenorrhea: Evaluate irregular bleeding or amenorrhea. ()

The following serious adverse reactions with the use of COCs are discussed elsewhere in the labeling:

Adverse reactions commonly reported by COC users are:

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).